Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCgamma, Crk, and Grb2. by Sparks, A. B. et al.
Proc. Natl. Acad. Sci. USA
Vol. 93, pp. 1540-1544, February 1996
Biochemistry
Distinct ligand preferences of Src homology 3 domains from Src,
Yes, Abl, Cortactin, p53bp2, PLCy, Crk, and Grb2
(signal transduction/protein-protein interactions/phage display)
ANDREW B. SPARKS*t, JAMES E. RIDERt, NoAH G. HOFFMANt, DANA M. FOWLKESt§, LAWRENCE A. QUILLIAM0,
AND BRIAN K. KAY*tIl**
*Curriculum in Genetics and Molecular Biology, Departments of tBiology, lPharmacology, and §Pathology, and IlLineberger Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, NC 27599; and tCytogen Corp., Princeton, NJ 08540-5237
Communicated by Clyde A. Hutchison III, University of North Carolina, Chapel Hill, NC, November 20, 1995 (received for review September 6,
1995)
ABSTRACT Src homology 3 (SH3) domains are con-
served protein modules 50-70 amino acids long found in a
variety of proteins with important roles in signal transduc-
tion. These domains have been shown to mediate protein-
protein interactions by binding short proline-rich regions in
ligand proteins. However, the ligand preferences of most SH3
domains and the role of these preferences in regulating
SH3-mediated protein-protein interactions remain poorly
defined. We have used a phage-displayed library of peptides of
the form X6PXXPX6 to identify ligands for eight different SH3
domains. Using this approach, we have determined that each
SH3 domain prefers peptide ligands with distinct sequence
characteristics. Specifically, we have found that the Src SH3
domain selects peptides sharing the consensus motif
LXXRPLPX'IP, whereas Yes SH3 selects WXXRPLPXLP,
Abl SH3 selects PPXOXPPP'IP, Cortactin SH3 selects
+PPIPXKPXWL, p53bp2 SH3 selects RPXIPIR+SXP,
PLCy SH3 selects PPVPPRPXXTL, Crk N-terminal SH3
selects IPILPWK, and Grb2 N-terminal SH3 selects
+ODXPLPXLP (where I, 0, and + represent aliphatic,
aromatic, and basic residues, respectively). Furthermore, we
have compared the binding of phage expressing peptides
related to each consensus motif to a panel of 12 SH3 domains.
Results from these experiments support the ligand prefer-
ences identified in the peptide library screen and evince the
ability of SH3 domains to discern subtle differences in the
primary structure of potential ligands. Finally, we have found
that most known SH3-binding proteins contain proline-rich
regions conforming to the ligand preferences of their respec-
tive SH3 targets.
Recent efforts to elucidate intracellular components of the
signal transduction apparatus have led to the discovery of a
series of conserved noncatalytic domains within a number of
signaling proteins. These domains, which include SH2, PTB,
and SH3 domains, are thought to mediate protein-protein
interactions by binding specific ligand sequences in target
proteins (reviewed in ref. 1). Initial understanding of the
nature of SH3 ligands derived from the identification of two
cDNA clones, 3BP1 and 3BP2, whose protein products bind
the Abl SH3 domain. The proteins both contain proline-rich
regions; peptides from these regions only 10 amino acids long
suffice as SH3 ligands (2). Subsequent studies have docu-
mented interactions between SH3 domains and proline-rich
ligands in a variety of physiological contexts. Such interactions
include that of Grb2 with SOS in growth factor-mediated
activation of Ras (3-5); those of Src, Lyn, and Fyn with the p85
subunit of phosphatidylinositol 3'-kinase (PI3K) in stimulation
of P13K activity (6, 7); and those of p47phOx and p67Phox with
p22Phox and p47phox, respectively, in assembly of the phagocyte
NADPH oxidase (8-10). From these and other studies, it is
clear that SH3 domains recognize proline-rich sequences; all
known SH3-binding proteins contain proline-rich regions with
at least one PXXP motif (11). However, the factors that
determine the specificity of SH3-mediated protein-protein
interactions have not been clearly defined.
Several recent reports suggest that one such factor may be
the capacity of different SH3 domains to recognize ligands
with distinct sequence characteristics. For example, phage-
displayed peptide libraries have been used to identify Src SH3
peptide ligands with the consensus sequence RPLPPLP (12,
13). These ligands display reduced binding to many other SH3
domains (12). Similarly, Yu et al. (14) used a synthetic peptide
library to identify Src and P13K SH3 ligands with the consensus
sequence RXLPPZP (Z = L for Src and R for P13K) and
demonstrated that each SH3 domain bound its respective
ligand with higher affinity than did the other.
In an effort to develop a more detailed understanding of the
specificity of SH3-ligand interactions, we have constructed a
phage-displayed library (termed the PXXP library) encoding
peptides of the form X6PXXPX6, where X represents any of
the 20 naturally occurring amino acids and P represents
invariant proline residues. Using this library, we have identi-
fied peptide ligands for SH3 domains of Src, Yes, Abl, Cor-
tactin, p53bp2, PLCy, Crk, and Grb2. Each SH3 domain
selects a set of peptide ligands sharing a distinct consensus
motif; these motifs reflect the unique ligand preferences of
each SH3 domain.
MATERIALS AND METHODS
Preparation of Glutathione S-Transferase (GST)-SH3 Fu-
sion Proteins. Constructs encoding GST fusions to the Grb2
N-terminal (Grb2 N, aa 1-58), Grb2 C-terminal (Grb2 C, aa
154-217), Nck N-terminal (Nck N, aa 1-68), Nck middle (Nck
M, aa 101-166), Nck C-terminal (Nck C, aa 191-257), p53bp2
(aa 454-530), or Src (aa 87-143) SH3 domains were generated
by PCR cloning of the appropriate cDNAs into pGEX-2T
(Pharmacia). The integrity of the constructs was confirmed by
DNA sequencing. pGEX-derived constructs expressing GST
fusions to the SH3 domains of Yes, Cortactin, Crk, Abl, and
PLC,y were kindly provided by M. Sudol (Rockefeller Uni-
versity), J. T. Parsons (University of Virginia), M. Matsuda
(National Institutes of Health, Tokyo), A. M. Pendergast
(Duke University), and S. Earp (University of North Carolina,
Chapel Hill), respectively. GST-SH3 fusion proteins were
prepared as described (15). The integrity and purity of the
fusion proteins were confirmed by SDS/PAGE. Protein con-
Abbreviations: SH3, Src homology 3; GST, glutathione S-transferase;
P13K, phosphatidylinositol 3'-kinase.
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centrations were determined using the BioRad protein assay
(Bio-Rad).
Phage-Displayed Peptide Library Construction. The PXXP
library was constructed as described (16). Peptides were
expressed as N-terminal fusions to the mature protein III of
bacteriophage M13. Two synthetic oligonucleotides (5'-
ctgtgcctcgagk(nnk)6cca(nnk)2cca(nnk)6tctagacgtgtcagt-3' and
5'-actgacacgtctaga-3', where k = g+t and n = g+a+t+c) were
annealed and filled in with Sequenase (Amersham). The
resulting DNA fragment was digested withXho I andXba I and
was ligated into gene III of a phage display vector (mBAX) that
allows for selection of recombinants by reversion of an amber
codon between the Xho I and Xba I sites of the vector. The
ligated DNA was electroporated into JS5 Escherichia coli and
recombinant phage were propagated on 200 100-mm 2x YT
(16 g of tryptone/10 g of yeast extract/5 g of NaCl/1 liter of
H20, autoclaved)/0.8% agar plates (17). To minimize the
recovery of sibling clones during affinity purification of bind-
ing phage, six distinct library fractions were prepared by
dividing the plates into six equal groups. Each fraction was
treated separately in all subsequent manipulations. Phage
particles were harvested from each fraction by diffusion into
100 ml of PBS (137 mM NaCl/2.7 mM KCl/4.3 mM
Na2HPO4/1.4 mM KH2PO4), concentrated by polyethylene
glycol precipitation (17), and resuspended in 10 ml of PBS/
10% glycerol. Each fraction contained -5 x 107 unique
recombinants, for a total library complexity of -3 x 108.
Affi'nity Purification of SH3-Binding Phage. Library screens
were performed as described (16). Briefly, wells of an ELISA
microtiter plate were coated with 10 jig of GST-SH3 fusion
protein in 100 mM NaHCO3 (pH 8.5) for 3 h and blocked with
Superblock (Pierce) for 1 h. Approximately 5 x 1011 infectious
particles from each library fraction were diluted in 200 ,ul of
PBS/0.1% Tween 20 and incubated in a GST-SH3-coated well
for 3 h. The wells were washed five times with PBS/0.1%
Tween 20, and bound phage were eluted with 50 mM
glycine HCl (pH 2.2). Recovered phage were propagated in 10
ml of 2x YT medium and 100 ,ul of a saturated DH5aF' E. coli
culture and affinity purified twice more as described above.
Affinity-purified phage were plated onto 2x YT/0.8% agar
plates to yield isolated plaques from which clonal phage stocks
and DNA were produced. Phage binding was confirmed by
incubating equal amounts of a clonal phage stock in wells
coated with 1 ,ug of GST-SH3 or GST. The wells were washed
five times with PBS/0.1% Tween 20, and bound phage were
detected by anti-phage ELISA according to the manufacturer's
instructions (Pharmacia). Clones with strong SH3-binding
activity were selected for further analysis. The sequences of
peptides displayed by these clones were determined by DNA
sequencing of phage inserts.
RESULTS AND DISCUSSION
PXXP Library Design and Screening. All known SH3
ligands contain at least one PXXP motif. We therefore de-
signed the PXXP library to encode peptides of the form
X6PXXPX6. This bias results in a population of peptides highly
enriched in SH3 ligands. In test screens of various phage-
displayed peptide libraries with the Src SH3 domain, the PXXP
library produced titers of SH3-binding phage 100-fold
greater than random peptide libraries of equivalent complexity
(data not shown). With a complexity of 3 x 108 unique clones,
the PXXP library has the capacity to encode all PXXP-
containing 7-mers with 99% confidence, assuming a Poisson
distribution of sequences within the library.
Immobilized GST-SH3 fusion proteins containing the Src,
Yes, N-Src, Abl, Cortactin, p53bp2, PLCy, Crk N, Grb2 N, and
Grb2 C SH3 domains were used to affinity purify SH3-binding
phage from each of the six fractions of the PXXP library. After
three rounds of affinity purification, phage titers were 102- to
105-fold higher than background for all SH3 constructs except
Grb2 C. Repeated attempts to enrich binding phage with Grb2
C SH3 met with failure. For each of the other SH3 domains,
four isolated clones from each of the six library fractions were
tested for binding to their respective SH3 targets; '90% of
tested clones exhibited strong SH3-binding activity and were
subsequently characterized. Although most clones were iso-
lated only once, several clones were recovered up to four times.
Significantly, sibling clones were never recovered from differ-
























































































































FIG. 1. Amino acid sequence of peptides expressed by SH3-binding
phage clones. Similar sequences within the peptides have been aligned
to yield the SH3 ligand consensus motifs, which are listed below each
group of peptides in boldface. Aliphatic, aromatic, and basic residues
are represented by the symbols I, 0, and +, respectively. Invariant
proline or flanking residues are underlined. *Clones used in subse-
quent assays. tPutative class II peptide (see text). 4Clone contained a
3-nucleotide deletion in the random peptide coding sequence.
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Table 1. Alignment and classification of SH3 ligand
consensus motifs




Grb2N +EDXPL P XLP




p53bp2 R P XT P P R + S X P
PLI'y XP PVP PRPXXTL
CrkN TPT'LPTK
Each SH3 ligand consensus motif was assigned to class I or II based
on its agreement with the class I or II consensus motif. Highly (>90%)
conserved positions in each SH3 ligand consensus motif are listed in
boldface and were interpreted as SH3 contact residues.
SH3 Ligand Consensus Motifs. Fig. 1 lists the amino acid
sequences of peptides expressed by SH3-binding clones. Sim-
ilar sequences within the peptides have been aligned to yield
consensus motifs; these motifs reflect the ligand preferences of
each SH3 domain.
SH3 domains from the closely related Src family members
Src and Yes select peptides sharing similar consensus motifs:
LXXRPLPXTP and TXXRPLPXLP, respectively. (In this
and subsequent motifs, P, 0, and + represent aliphatic,
aromatic, and basic residues, respectively.) Previously, we (12)
and others (13, 14) have shown that Src SH3 selects peptides
with the consensus sequence RPLPPLP; peptides containing
this sequence exhibit significant binding to the SH3 domains of
several other Src family members (A.B.S. and B.K.K., unpub-
lished data). Similarly, Rickles et al. (18) have recently dem-
onstrated that SH3 domains from the Src family members Src,
Lyn, and Fyn select peptides with the consensus sequence
RPLPPLPXP, RXXRPLPPLPxP, and RPLPP(I/L)P, respec-
tively. Taken together, these data suggest that the closely
related Src, Yes, Lyn, and Fyn SH3 domains possess very
similar ligand preferences.
Whereas the Src family SH3 domains select similar peptides,
more distantly related SH3 domains exhibit distinct ligand
preferences (Fig. 1). For example, Abl SH3 selects peptides
sharing the consensus motif PPXOXPPPTP. This motif is
consistent with sequences found in Abl SH3-binding proteins
(see below) as well as a recently identified Abl ligand consen-
sus motif (PPPYPPPPLP) (18). The Cortactin and p53bp2
SH3 domains are unique in that they both select peptide
ligands with conserved positively charged residues flanking the
PXXP core; Cortactin SH3 prefers +PPPPXKPXWL and
p53bp2 prefers RPX4PTR+SXP. In contrast, PLCy SH3 and
Crk N SH3 both select peptides with a conserved basic residue
C terminal of the PXXP core; PLCy SH3 prefers PPVP-
PRPXXTL and Crk N SH3 prefers A'P'ILP'IK. Finally, Grb2
N SH3 selects ligands with the consensus +ODXPLPXLP.
Interestingly, Grb2 N SH3 ligands may be grouped into three
subpopulations sharing related consensus motifs +ODX-
PLPXLP, YOX+PLPXLP, and ODPLPXLP. Thus, each of
the SH3 domains we have investigated selects peptide ligands
with distinct sequence characteristics.
SH3 Ligand Binding Orientation. Peptide ligands bound to
SH3 domains have been shown to assume a left-handed
polyproline type II (PPII) helix conformation (14). SH3 li-










































FIG. 2. Relative binding of SH3-selected phage clones to various SH3 domains. Two clones (A and B) representing each consensus motif were
assayed for binding to 1 ,ug of each immobilized GST-SH3 fusion protein. Bound phage were detected by anti-phage ELISA. Sequences of peptides
displayed by each clone are aligned with their respective consensus motifs. Invariant proline residues are underlined. Solid bars, specific binding;
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two opposite orientations (19). Feng et al. (19) have demon-
strated that peptides that bind in one or the other orientation
share different consensus motifs. Specifically, ligands that bind
in the class I or class II orientation conform to the consensus
+pTPpTP or TPpTPp+, respectively, where uppercase po-
sitions represent conserved residues that contact the SH3
domain and confer specificity, and lowercase positions repre-
sent scaffolding residues that tend to be proline.
According to this model, we predict that the peptides
selected by the Src, Yes, Abl, and Grb2 N SH3 domains bind
in the class I orientation, whereas the peptides selected by the
Cortactin, p53bp2, PLCy, and Crk N SH3 domains bind in the
class II orientation (Table 1). Interestingly, most of the SH3
ligand consensus motifs identified in this work contain addi-
tional conserved residues flanking the SH3-binding core de-
fined by Feng et al. (19). Furthermore, these conserved
residues are situated N and C terminal of the SH3-binding core
in class I and class II motifs, respectively, and are therefore
predicted to interact with equivalent regions of their target
SH3 domains (Table 1).
The Src SH3 domain is capable of binding both class I and
class II peptides (19). Although class I peptides predominate
the population of Src SH3 ligands selected from the PXXP
library, one clone conforms well to the class II consensus (Fig.
1). Previously, we (12) and others (14) have isolated class II Src
SH3 ligands sharing the consensus PP4IPPR. Similarly,
whereas the Grb2 N SH3 domain has been shown to bind
peptides from SOS with the class II consensus sequence
PPTPPR (5), we have isolated Grb2 N SH3 ligands that
conform to the class I consensus (Table 1). Thus, both the Src
and the Grb2 N SH3 domains apparently have the capacity to
bind both class I and class II peptide ligands.
Despite the availability of both class I and II ligands in the
PXXP library and the ability of at least some SH3 domains to
bind both class I and II ligands, we have found that each of the
SH3 domains investigated in this work tends to select ligands
that bind in one particular orientation. Whether this bias
reflects the preferences of different SH3 domains for ligands
that bind in a particular orientation or biases inherent in the
phage selection process is not known.
SH3 Ligand Binding Characteristics. To explore further the
capacity of SH3 domains to discriminate between different
SH3 ligands, we investigated the binding of phage expressing
various peptide ligands to a panel ofSH3 domains. Equal titers
of clonal phage stocks were incubated in microtiter wells
coated with different GST-SH3 fusion proteins. The wells
were washed several times, and bound phage were detected
with an anti-phage antibody (Fig. 2). Positive ELISA signals
were equivalent to those obtained with previously character-
ized Src SH3-binding clones (12) and are indicative of
SH3:peptide affinities in the 5-75 ,M range (14, 18). Whereas
the Src, Yes, Crk, and Grb2 N SH3 domains cross-reacted with
a few phage clones selected with other SH3 domains, the Abl,
Cortactin, p53bp2, and PLCy SH3 domains displayed consid-
erable specificity. Significantly, only 33 of 220 potential in-
stances of cross-reactivity were observed, suggesting that SH3
selectivity is the rule rather than the exception.
Each instance of cross-reactivity may be explained by sim-
ilarities between the sequences of the peptides and the ligand
preferences of the cross-reactive SH3 domains. For example,
Crk SH3 cross-reacted with three phage clones selected with
other SH3 domains; each of these clones coincidentally ex-
pressed peptides conforming to the Crk SH3 preferred ligand
consensus motif. Similarly, the cross-reactivity observed be-
tween the Src, Yes, and Grb2 SH3 domains and clones selected
by other SH3 domains within this group may be a consequence
of the fact that these SH3 domains prefer the same proline-rich
core. Finally, the Src and Yes SH3 domains cross-reacted with
the PLCySH3 ligand MPPPVPPRPPGTL, which contains the
class II Src SH3-binding sequence PPVPPR. Taken together,
these data demonstrate the capacity of SH3 domains to discern
subtle differences in the primary structure of potential ligands.
Natural SH3 Ligands: SH3-Binding Proteins. To evaluate
the contribution of SH3 selectivity to natural SH3-ligand
interactions, we have compared the SH3 ligand consensus
motifs with sequences of known SH3-binding proteins (Fig. 3).
The Src SH3-binding proteins Dynamin, hnRNP K, p62, PI3K
p85, and Shb all possess proline-rich regions conforming to the
Src SH3 class I or II consensus motifs. However, the Src
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FIG. 3. Alignment of sequences from SH3-binding proteins. Se-
quences of proteins known to interact with each SH3 domain were
compared to its ligand consensus motif(s). Cortactin SH3-binding
proteins have not been reported. Each entry lists species and protein
from which the sequence was derived. Amino acid positions of each
sequence are listed in parentheses. Residues within protein sequences
agreeing with highly (>90%) conserved residues in the consensus
motifs are listed in boldface. *Protein sequences previously demon-
strated to bind their respective SH3 domain.
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SH3-binding proteins AFAP-110, CDC42 GAP, and Shc con-
tain sequences lacking at least one critical consensus residue.
Each of the Abl, Crk, and PLCy SH3-binding proteins possess
at least one proline-rich region conforming to the consensus
motifs of their respective SH3 targets. Most of the Grb2-
binding proteins do not possess sequences conforming to the
class I Grb2 N SH3 ligand motif identified in the random
peptide screen. However, each Grb2-binding protein contains
at least one region in agreement with the class II Grb2 N SH3
motif derived from Grb2-binding sequences in SOS. Why Grb2
selects class I peptide ligands yet seems to prefer class II
protein ligands is unknown.
Thus, most of the SH3-binding proteins contain proline-rich
regions conforming to the ligand consensus motifs of their
respective SH3 targets. Many of these regions have been
implicated in SH3 binding. However, the sequences responsi-
ble for SH3 recognition by several of these proteins have not
been clearly defined. The sequences listed in Fig. 3 represent
a reasonable starting point for future investigations.
Several of the SH3-binding proteins possess proline-rich
regions that do not conform to the consensus motifs of their
respective SH3 targets, suggesting that factors other than the
local structure of the ligand may contribute to the regulation
of SH3-mediated protein-protein interactions in vivo. Such
factors might include subcellular localization of SH3 or ligand
proteins, cooperativity between different binding domains
within a protein or complex of proteins, steric limitations upon
the access of an SH3 domain to its ligands, and the existence
of discontinuous SH3-binding regions in folded proteins.
Similarities between the SH3 ligand preferences and sequences
in naturally occurring SH3-binding proteins suggest that these
preferences may reflect functionally significant biases of different
SH3 domains for specific sequences within target proteins. Thus,
we have searched several protein data bases for sequences related
to each of the SH3 ligand consensus motifs. By identifying
putative SH3-binding sites in candidate proteins, this approach
can yield testable predictions regarding specific SH3-mediated
protein-protein interactions in vivo. These searches identified
most of the sequences listed in Fig. 3 as well as sequences in
a large number of proteins not previously implicated in SH3
interactions. The results are available via the Internet: http://
www.unc.edu/depts/biology/kayref.html.
Note Added in Proof. After acceptance of this manuscript for publi-
cation, a paper was published describing the use of biased phage
libraries to analyze the ligand preferences of the Src, Lyn, Fyn, Yes,
and PI3K SH3 domains (33).
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